471
Views
2
CrossRef citations to date
0
Altmetric
Retracted Article

RETRACTED ARTICLE: miR-15b-3p promotes the malignant progression of endometrial cancer cells through targeting KLF2

, , , &
Pages 1431-1440 | Received 09 Dec 2020, Accepted 08 Jun 2021, Published online: 05 Jul 2021
 

Statement of Retraction

We, the Editors and Publisher of the journal Cell Cycle, have retracted the following article:

Ping Wang, Xiqing Zhao, Xiaotang Wu, Guoshuai Tang, and Linna Yuan. miR-15b-3p promotes the malignant progression of endometrial cancer cells through targeting KLF2. Cell Cycle. 2021;20(14):1431-1440. doi: 10.1080/15384101.2021.1941611

Since publication, concerns have been raised about the integrity of the data in the article. When approached for an explanation, the authors have been unable to address all the concerns raised. As verifying the validity of published work is core to the integrity of the scholarly record, we are therefore retracting the article. The authors do not agree with the retraction.

We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as ‘Retracted’.

View retraction statement:
Statement of Retraction: miR-15b-3p promotes the malignant progression of endometrial cancer cells through targeting KLF2

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.